Fubotv earnings beat by $0.10, revenue topped estimates
SAN DIEGO - Illumina, Inc. (NASDAQ: ILMN) and Ovation.io have announced the creation of a substantial clinical multiomic dataset, encompassing data from 25,000 patients who have undergone treatment with GLP-1 receptor agonist therapies. This dataset, the largest of its kind to be made commercially available, is expected to propel the development of new GLP-1 therapies and the discovery of novel drug targets, particularly for patients who currently do not respond to existing treatments. While Illumina generated $4.37 billion in revenue over the last twelve months, InvestingPro analysis indicates the company is currently operating at a loss, though analysts expect profitability to return this year.
The dataset integrates phenotypic, genomic, and proteomic data and is aimed at fostering a deeper understanding of the molecular pathways involved in the response to GLP-1 therapies. This could lead to the identification of new biomarkers and drug targets for non-responsive patients and expand the indications for GLP-1 therapies.
According to a 2024 health tracking poll by the Kaiser Family Foundation, one in eight adults in the United States have used a GLP-1 receptor agonist. However, a study published in Diabetes & Metabolic Syndrome in 2024 highlighted that about 40% of users with Type 2 diabetes do not respond effectively to these therapies. The new dataset is designed to address this significant therapeutic gap.
Todd Christian, senior vice president at Illumina, emphasized the dataset’s potential to revolutionize the next generation of metabolic disease treatments, ensuring broader patient benefits. Marty Miller, chief revenue officer of Ovation, also expressed pride in the collaboration, which aims to provide the pharmaceutical industry with the necessary insights to understand the varying effectiveness of GLP-1 receptor agonists among individual patients. According to InvestingPro data, Illumina maintains a strong gross profit margin of 68.37%, demonstrating operational efficiency despite recent market challenges that have led to a 48% decline in share price over the past six months. InvestingPro analysis suggests the stock is currently undervalued.
The initiative leverages Illumina’s next-generation sequencing (NGS) technologies, including the sequencing of 25,000 whole genomes and protein expression profiling of 5,000 samples. The dataset will include a longitudinal subset of proteomes from samples collected before and after patient exposure to GLP-1 therapy.
Ovation.io contributes to this effort with samples from its biobank, which contains over 1.7 million de-identified, consented, and tokenized samples, linked to comprehensive phenotypic data.
This collaboration builds on an initial agreement between Illumina and Ovation in 2024, which aimed to create pilot datasets for various diseases. The companies plan to scale the GLP-1 dataset for future research and development efforts. For investors seeking deeper insights, InvestingPro offers comprehensive analysis with over 30 additional financial metrics and exclusive ProTips, available in the detailed Research Report covering Illumina among 1,400+ top US stocks.
The information in this article is based on a press release statement.
In other recent news, Illumina reported significant developments that may interest investors. Piper Sandler has maintained an Overweight rating on Illumina with a price target of $190, citing the company’s strong competitive advantage in the sequencing space and potential for growth in clinical sequencing. They also noted that Illumina’s recent stock decline reflects industry concerns about competition and NIH funding. Meanwhile, TD Cowen has adjusted its financial outlook for Illumina, reducing the price target to $86 and maintaining a Hold rating due to concerns over NIH funding pressures impacting earnings.
Additionally, Illumina and Tempus have announced a partnership to advance AI in genomic sequencing, aiming to improve patient care across various disease categories. The collaboration will leverage Illumina’s AI technologies and Tempus’s data platform to develop genomic algorithms. In another update, Bernstein SocGen Group has maintained a Market Perform rating and a $130 price target for Illumina, following changes to the company’s board of directors. Keith Meister, associated with activist investor Carl Icahn, has joined the board, signaling potential shifts in strategy or governance. These recent developments highlight the dynamic environment Illumina is navigating, with a mix of strategic partnerships and financial evaluations by analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.